CARIBOU BIOSCIENCES INC (CRBU) Stock Price, Quote, News and Overview
NASDAQ:CRBU - Nasdaq - US1420381089 - Common Stock - Currency: USD
CRBU Quote, Performance and Key Statistics
1.31
-0.1 (-7.09%)
The current stock price of CRBU is 1.31 USD. In the past month the price decreased by -13.82%. In the past year, price decreased by -81.12%.
CRBU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CRBU
Company Profile
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 158 full-time employees. The company went IPO on 2021-07-23. The company is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Company Info
CARIBOU BIOSCIENCES INC
2929 7Th Street, Ste 120
Berkeley CALIFORNIA US
Employees: 158
Company Website: https://www.cariboubio.com/
Investor Relations: https://investor.cariboubio.com/
Phone: 15109826030
CARIBOU BIOSCIENCES INC / CRBU FAQ
What is the stock price of CARIBOU BIOSCIENCES INC today?
The current stock price of CRBU is 1.31 USD. The price decreased by -7.09% in the last trading session.
What is the ticker symbol for CARIBOU BIOSCIENCES INC stock?
The exchange symbol of CARIBOU BIOSCIENCES INC is CRBU and it is listed on the Nasdaq exchange.
On which exchange is CRBU stock listed?
CRBU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CARIBOU BIOSCIENCES INC stock?
15 analysts have analysed CRBU and the average price target is 13.52 USD. This implies a price increase of 931.68% is expected in the next year compared to the current price of 1.31. Check the CARIBOU BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CARIBOU BIOSCIENCES INC worth?
CARIBOU BIOSCIENCES INC (CRBU) has a market capitalization of 118.62M USD. This makes CRBU a Micro Cap stock.
How many employees does CARIBOU BIOSCIENCES INC have?
CARIBOU BIOSCIENCES INC (CRBU) currently has 158 employees.
What are the support and resistance levels for CARIBOU BIOSCIENCES INC (CRBU) stock?
CARIBOU BIOSCIENCES INC (CRBU) has a resistance level at 1.34. Check the full technical report for a detailed analysis of CRBU support and resistance levels.
Is CARIBOU BIOSCIENCES INC (CRBU) expected to grow?
The Revenue of CARIBOU BIOSCIENCES INC (CRBU) is expected to decline by -70.59% in the next year. Check the estimates tab for more information on the CRBU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CARIBOU BIOSCIENCES INC (CRBU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRBU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRBU, evaluating the profitability, health, valuation and growth aspects
- CARIBOU BIOSCIENCES INC (CRBU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CARIBOU BIOSCIENCES INC (CRBU) Sales and EPS estimates to see what analysts future expectations are.
- CARIBOU BIOSCIENCES INC (CRBU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CARIBOU BIOSCIENCES INC (CRBU) Insider and Institutional Ownership to learn about the owners and their transactions.
- CARIBOU BIOSCIENCES INC (CRBU) Stock Chart to make your own analysis
- CARIBOU BIOSCIENCES INC (CRBU) Latest news and press-releases to stay up to date.
Does CARIBOU BIOSCIENCES INC (CRBU) stock pay dividends?
CRBU does not pay a dividend.
What is the Price/Earnings (PE) ratio of CARIBOU BIOSCIENCES INC (CRBU)?
CARIBOU BIOSCIENCES INC (CRBU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
What is the Short Interest ratio of CARIBOU BIOSCIENCES INC (CRBU) stock?
The outstanding short interest for CARIBOU BIOSCIENCES INC (CRBU) is 10.98% of its float. Check the ownership tab for more information on the CRBU short interest.
CRBU Technical Analysis
CRBU Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRBU. While CRBU has a great health rating, there are worries on its profitability.
CRBU Financial Highlights
Over the last trailing twelve months CRBU reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS decreased by -10% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.02% | ||
| ROE | -52.67% | ||
| Debt/Equity | 0 |
CRBU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CRBU. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -16.64% and a revenue growth -70.59% for CRBU